## Christian J Wiedermann

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4616854/christian-j-wiedermann-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

3,187 140 32 52 h-index g-index citations papers 163 3,673 5.7 5.59 L-index avg, IF ext. papers ext. citations

#	Paper	IF	Citations
140	Health information-seeking behavior associated with linguistic group membership: latent class analysis of a population-based cross-sectional survey in Italy, August to September 2014 <i>Archives of Public Health</i> , <b>2022</b> , 80, 87	2.6	O
139	Human albumin and 6% hydroxyethyl starches (130/0.4) in cardiac surgery: a meta-analysis revisited <i>BMC Surgery</i> , <b>2022</b> , 22, 140	2.3	0
138	Further Retractions of Articles by Joachim Boldt. <i>Critical Care Medicine</i> , <b>2022</b> , 50, e601-e603	1.4	O
137	Who Is Watching the Children? A Quantitative Analysis of Strategies for Reconciling Work and Parenting during Lockdown in Northern Italy. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	1
136	Safety of tetrastarch in surgical patients: a meta-analysis revisited. Comment on Br J Anaesth 2021; 127: 556-568. <i>British Journal of Anaesthesia</i> , <b>2021</b> ,	5.4	
135	Hypoalbuminemia as Surrogate and Culprit of Infections. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	16
134	Clinical Trials in Volume Resuscitation with Hydroxyethyl Starch: Focus on Risk of Bias. <i>Turkish Journal of Anaesthesiology and Reanimation</i> , <b>2020</b> , 48, 258-260	0.7	1
133	Meet the New Hydroxyethyl Starch, Same as the Old Hydroxyethyl Starch?. <i>Anesthesia and Analgesia</i> , <b>2020</b> , 131, e87-e88	3.9	1
132	Phases of fluid management and the roles of human albumin solution in perioperative and critically ill patients. <i>Current Medical Research and Opinion</i> , <b>2020</b> , 36, 1961-1973	2.5	9
131	Acquired deficiency of prothrombin complex coagulation factors in major bleeding is a therapeutic indication of 4-factor prothrombin complex concentrates. <i>Transfusion Medicine</i> , <b>2020</b> , 30, 527	1.3	
130	Anticoagulant therapy for septic coagulopathy and disseminated intravascular coagulation: where do KyberSept and SCARLET leave us?. <i>Acute Medicine &amp; Surgery</i> , <b>2020</b> , 7, e477	1.7	3
129	Ambiguity about the volume of colloids administered in a clinical study of thoracic esophagectomy precludes conclusions on the renal safety of hydroxyethyl starch. <i>Surgery Today</i> , <b>2019</b> , 49, 885	3	1
128	Hypoalbuminemia and the Risk of Acute Kidney Injury in Sepsis. <i>Critical Care Medicine</i> , <b>2019</b> , 47, e377-e	3 <b>7</b> 8µ	4
127	Inaction over retractions of identified fraudulent publications: ongoing weakness in the system of scientific self-correction. <i>Accountability in Research</i> , <b>2018</b> , 25, 239-253	1.9	7
126	Antithrombin concentrate use in disseminated intravascular coagulation of sepsis: meta-analyses revisited. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 16, 455-457	15.4	22
125	Undisclosed conflicts of interest in German-language textbooks of anesthesiology, critical care, and emergency medicine. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , <b>2018</b> , 139, 53-58	1.4	
124	The Boldt scandal still in need of action: the example of colloids 10 years after initial suspicion of fraud. <i>Intensive Care Medicine</i> , <b>2018</b> , 44, 1735-1737	14.5	2

123	Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency. <i>Journal of Pharmaceutical Policy and Practice</i> , <b>2017</b> , 10, 12	3.2	31
122	Causal relationship between hypoalbuminemia and acute kidney injury. <i>World Journal of Nephrology</i> , <b>2017</b> , 6, 176-187	3.6	39
121	Failure of Propensity Scores in Overcoming the Tendency to Use Albumin as Salvage Treatment in Sicker Patients. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , <b>2017</b> , 31, e99	2.1	
120	Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Insufficient Evidence to Support the Use of Hydroxyethyl Starch. <i>Indian Journal of Hematology and Blood Transfusion</i> , <b>2017</b> , 33, 445-447	0.7	
119	Bodybuilding-induced Mondorß disease of the chest wall. <i>Physical Therapy in Sport</i> , <b>2017</b> , 23, 133-135	3	7
118	Acute kidney injury in critically burned patients treated with hydroxyethyl starch: a response to SBchez-SBchez et al. <i>Annals of Burns and Fire Disasters</i> , <b>2017</b> , 30, 220-221	0.8	
117	A word of caution on renal risks of prothrombin complex concentrate use in cardiac surgery. <i>Critical Care</i> , <b>2016</b> , 20, 63	10.8	2
116	Ethical publishing in intensive care medicine: A narrative review. <i>World Journal of Critical Care Medicine</i> , <b>2016</b> , 5, 171-9	3	10
115	Medication Error When Switching from Warfarin to Rivaroxaban Leading to Spontaneous Large Ecchymosis of the Abdominal and Chest Wall. <i>Clinics and Practice</i> , <b>2016</b> , 6, 873	2.4	4
114	Fluid management in sepsis: The potential beneficial effects of albumin. <i>Journal of Critical Care</i> , <b>2016</b> , 35, 161-7	4	58
113	Study citation irrespective of retraction status. <i>Journal of Clinical Anesthesia</i> , <b>2016</b> , 34, 517	1.9	1
112	Impairment of innate immune function by hydroxyethyl starch. <i>British Journal of Anaesthesia</i> , <b>2016</b> , 117, 260	5.4	4
111	Albumin to Reduce Mortality in Cirrhotic Patients with Acute Kidney Injury <b>2016</b> , 133-141		
110	Hydroxyethyl Starch, Acute Kidney Injury, and Mortality <b>2016</b> , 163-174		
109	Pilot study on the effects of a 2-week hiking vacation at moderate versus low altitude on plasma parameters of carbohydrate and lipid metabolism in patients with metabolic syndrome. <i>BMC Research Notes</i> , <b>2015</b> , 8, 103	2.3	10
108	The use of meta-analyses for benefit/risk re-evaluations of hydroxyethyl starch. <i>Critical Care</i> , <b>2015</b> , 19, 240	10.8	3
107	Propensity matching cannot substitute for randomization in albumin studies. <i>Critical Care</i> , <b>2015</b> , 19, 20	<b>6</b> 10.8	5

105	Beautiful small: Misleading large randomized controlled trials? The example of colloids for volume resuscitation. <i>Journal of Anaesthesiology Clinical Pharmacology</i> , <b>2015</b> , 31, 394-400	1.3	7
104	Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review. <i>Intensive Care Medicine</i> , <b>2014</b> , 40, 160-70	14.5	72
103	Reporting bias in trials of volume resuscitation with hydroxyethyl starch. <i>Wiener Klinische Wochenschrift</i> , <b>2014</b> , 126, 189-94	2.3	12
102	Length of stay as risk factor for inappropriate hospital days: interaction with patient age and co-morbidity. <i>Journal of Evaluation in Clinical Practice</i> , <b>2013</b> , 19, 80-5	2.5	17
101	Concerns about renal safety of HES 130. Critical Care, 2013, 17, 444	10.8	1
100	Chloride-restrictive fluid administration and incidence of acute kidney injury. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 543	27.4	2
99	Hydroxyethyl starch 130/0.4: safe for the kidney in surgical patients?. <i>Anesthesiology</i> , <b>2013</b> , 119, 735-6	4.3	2
98	Increased mortality after infusion of "modern" hydroxyethyl starch. <i>Swiss Medical Weekly</i> , <b>2013</b> , 143, w13747	3.1	7
97	Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies. <i>Clinical Pharmacokinetics</i> , <b>2012</b> , 51, 225-36	6.2	70
96	From persistence to palliation: limiting active treatment in the ICU. <i>Current Opinion in Critical Care</i> , <b>2012</b> , 18, 693-9	3.5	6
95	Volumentherapie-Knowhow. CME (Berlin, Germany), 2012, 9, 8-17	O	
94	Mortality after hydroxyethyl starch 130/0.4 infusion: an updated meta-analysis of randomized trials. <i>Swiss Medical Weekly</i> , <b>2012</b> , 142, w13656	3.1	12
93	Awareness and use of recommendations for withholding and withdrawing therapy in Austrian intensive care units. <i>Wiener Medizinische Wochenschrift</i> , <b>2011</b> , 161, 99-102	2.9	2
92	Inappropriate hospital admission: interaction between patient age and co-morbidity. <i>Internal and Emergency Medicine</i> , <b>2011</b> , 6, 361-7	3.7	18
91	Mesenteric panniculitis presenting with acute non-occlusive colonic ischemia. <i>International Archive of Medicine</i> , <b>2011</b> , 4, 22		8
90	Hypoalbuminemia as a Risk Factor for Acute Kidney Injury. <i>Annual Update in Intensive Care and Emergency Medicine</i> , <b>2011</b> , 233-241	0.2	2
89	Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. <i>Critical Care</i> , <b>2010</b> , 14, R191	10.8	92
88	Bacillus species infective arthritis after knee arthroscopy. <i>Surgical Infections</i> , <b>2010</b> , 11, 555-8	2	4

### (2007-2010)

87	Iatrogenic hypoalbuminemia due to hydroxyethyl starch 130/0.4: a risk factor for acute kidney injury?. <i>Anesthesia and Analgesia</i> , <b>2010</b> , 110, 1242; author reply 1243	3.9	1
86	Ciprofloxacin-induced acute haemolytic anaemia in a patient with glucose-6-phosphate dehydrogenase Mediterranean deficiency: a case report. <i>Annals of Hematology</i> , <b>2010</b> , 89, 935-7	3	13
85	Hypoalbuminemia and acute kidney injury: a meta-analysis of observational clinical studies. <i>Intensive Care Medicine</i> , <b>2010</b> , 36, 1657-65	14.5	137
84	Digital clubbing in primary intestinal lymphangiectasia: a case report. <i>Wiener Medizinische Wochenschrift</i> , <b>2010</b> , 160, 431-6	2.9	3
83	Enhancement of fibrinogen-triggered pro-coagulant activation of monocytes in vitro by matrix metalloproteinase-9. <i>Thrombosis Journal</i> , <b>2010</b> , 8, 2	5.6	11
82	Resuscitation with hyperoncotic colloids in the intensive care unit. <i>Intensive Care Medicine</i> , <b>2009</b> , 35, 381; author reply 382-3	14.5	4
81	Warfarin-induced bleeding complications - clinical presentation and therapeutic options. <i>Thrombosis Research</i> , <b>2008</b> , 122 Suppl 2, S13-8	8.2	59
80	Reduced watery diarrhea during pregnancy in a psoriasis patient with lymphocytic colitis. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2008</b> , 46, 1275-7	1.6	1
79	Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial. <i>Anesthesia and Analgesia</i> , <b>2008</b> , 107, 1633-8	3.9	19
78	Recommendations on therapy limitation and therapy discontinuation in intensive care units: Consensus Paper of the Austrian Associations of Intensive Care Medicine. <i>Intensive Care Medicine</i> , <b>2008</b> , 34, 771-6	14.5	24
77	End-of-life decisions in Austriaß intensive care units. <i>Intensive Care Medicine</i> , <b>2008</b> , 34, 1142-4	14.5	3
76	Precordial T-wave inversion of "cardiac memory" pattern after high-dose methylprednisolone pulse therapy. <i>Internal and Emergency Medicine</i> , <b>2008</b> , 3, 375-8	3.7	2
75	Non-episodic angioedema associated with eosinophilia following Mycoplasma pneumoniae infection. <i>Clinical Rheumatology</i> , <b>2008</b> , 27, 1573-6	3.9	10
74	Scoring fildisseminierte intravaskulfe Gerinnung (DIC) in der Intensivmedizin. <i>Intensivmedizin Und Notfallmedizin</i> , <b>2008</b> , 45, 205-211		1
73	Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. <i>BMC Emergency Medicine</i> , <b>2008</b> , 8, 1	2.4	96
72	Emergency correction of coagulation before major surgery in two elderly patients on oral anticoagulation. <i>Thrombosis Journal</i> , <b>2007</b> , 5, 1	5.6	7
71	Deferred consent in emergency intensive care research: what if the patient dies early? Use the data or not?. <i>Intensive Care Medicine</i> , <b>2007</b> , 33, 894-900	14.5	48
70	Case involving end-of-life decision issues in Italy. <i>Intensive Care Medicine</i> , <b>2007</b> , 33, 1041-2	14.5	9

69	Immunomodulation by alpha(1)-proteinase inhibitor: lack of chemotactic effects of recombinant human alpha(1)-proteinase inhibitor from yeast on human peripheral blood granulocytes. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , <b>2007</b> , 55, 399-403	4	
68	Lymphocytic colitis in a patient with psoriasis responsive to budesonide. <i>Scandinavian Journal of Gastroenterology</i> , <b>2007</b> , 42, 538-9	2.4	6
67	Do plasma substitutes have additional properties beyond correcting volume deficits?: Shock 25:2103-116, 2006. <i>Shock</i> , <b>2007</b> , 27, 339-42	3.4	1
66	Effects of anticoagulant strategies on activation of inflammation and coagulation. <i>Expert Opinion on Biological Therapy</i> , <b>2007</b> , 7, 855-70	5.4	33
65	Renal failure in septic patients receiving hydroxyethyl starch. <i>Minerva Anestesiologica</i> , <b>2007</b> , 73, 441; author reply 442	1.9	2
64	Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis. <i>Critical Care</i> , <b>2006</b> , 10, 209	10.8	56
63	Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 95, 850-856	7	69
62	High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. <i>Critical Care Medicine</i> , <b>2006</b> , 34, 285-92	1.4	144
61	Baseline severity of sepsis in subjects of the prowess and the Kybersept clinical trials on endogenous anticoagulants. <i>Shock</i> , <b>2006</b> , 25, 657-8	3.4	3
60	A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. <i>Blood Coagulation and Fibrinolysis</i> , <b>2006</b> , 17, 521-6	1	55
59	Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. <i>Journal of Thrombosis and Haemostasis</i> , <b>2006</b> , 4, 90-7	15.4	288
58	The European Clinical Trials Directive revisited: the VISEAR recommendations. <i>Resuscitation</i> , <b>2006</b> , 69, 9-14	4	22
57	Recommendations in relation to the EU clinical trials directive and medical research involving incapacitated adults. <i>Wiener Klinische Wochenschrift</i> , <b>2006</b> , 118, 183-91	2.3	10
56	When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated). <i>Intensive Care Medicine</i> , <b>2006</b> , 32, 604; author reply 610-2	14.5	13
55	Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 95, 850-6	7	21
54	Src tyrosine kinase-dependent migratory effects of antithrombin in leukocytes. <i>Experimental Cell Research</i> , <b>2005</b> , 305, 214-20	4.2	6
53	Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis. <i>Critical Care</i> , <b>2005</b> , 9, R596-600	10.8	9
52	Bioethics, the Surviving Sepsis Campaign, and the industry. <i>Wiener Klinische Wochenschrift</i> , <b>2005</b> , 117, 442-4	2.3	14

### (2001-2005)

51	A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis. <i>BMC Emergency Medicine</i> , <b>2005</b> , 5, 7	2.4	33	
50	Expression and function of syndecan-4 in human platelets. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 93, 1120	)- <i>7</i> <sub>7</sub>	17	
49	Attenuation of leukocyte beta 2-integrin expression by antithrombin-III. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2004</b> , 17, 27-32	3	14	
48	Syndecan-4-dependent migration of human eosinophils. Clinical and Experimental Allergy, <b>2004</b> , 34, 696	5- <b>7</b> 03	14	
47	Hydroxyethyl starchcan the safety problems be ignored?. Wiener Klinische Wochenschrift, <b>2004</b> , 116, 583-94	2.3	50	
46	Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis. <i>Annals of Medicine</i> , <b>2004</b> , 36, 194-203	1.5	20	
45	Improvement in coagulation markers with antithrombinbeneficial in severe sepsis?. <i>Critical Care Medicine</i> , <b>2004</b> , 32, 1968-9	1.4	5	
44	Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. <i>Journal of Allergy and Clinical Immunology</i> , <b>2003</b> , 112, 375-81	11.5	60	
43	Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. <i>Thrombosis and Haemostasis</i> , <b>2003</b> , 90, 1150-7	7	58	
42	Inhibition of human neutrophil chemotaxis toward interleukin 8 with six clinical antithrombin concentrates in vitro. <i>Intensive Care Medicine</i> , <b>2002</b> , 28, 1447-52	14.5	5	
41	Adverse Effect of Heparin on Antithrombin Action during Endotoxemia: Microhemodynamic and Cellular Mechanisms. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 88, 242-252	7	59	
40	Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. <i>Journal of Cell Science</i> , <b>2002</b> , 115, 227-36	5.3	51	
39	Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. <i>Thrombosis and Haemostasis</i> , <b>2002</b> , 88, 242-52	7	12	
38	Plasma levels of procalcitonin and interleukin-6 in acute myocardial infarction. <i>Inflammation</i> , <b>2001</b> , 25, 97-100	5.1	31	
37	Syndecan-4 as antithrombin receptor of human neutrophils. <i>Biochemical and Biophysical Research Communications</i> , <b>2001</b> , 287, 42-6	3.4	75	
36	Theoretical basis for the activity of thalidomide. <i>BioDrugs</i> , <b>2001</b> , 15, 681-703	7.9	45	
35	The inhibition of oxygen radical release from human neutrophils by resting platelets is reversed by administration of acetylsalicylic acid or clopidogrel. <i>Free Radical Research</i> , <b>2001</b> , 34, 461-6	4	12	
34	Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. <i>Blood</i> , <b>2001</b> , 97, 1079-85	2.2	89	

33	The role of immune activation in endotoxin-induced atherogenesis. <i>Journal of Endotoxin Research</i> , <b>2001</b> , 7, 322-6		7
32	Pentoxifylline-augmented antiproliferative effects of adrenomedullin on vascular smooth muscle cells. <i>European Journal of Heart Failure</i> , <b>2000</b> , 2, 257-60	12.3	2
31	Neuropeptide-induced chemotaxis of eosinophils in pulmonary diseases. <i>Annals of Medicine</i> , <b>2000</b> , 32, 429-39	1.5	16
30	Inhibition of human peripheral blood neutrophil respiratory burst by alcohol-based venipuncture site disinfection. <i>Vaccine Journal</i> , <b>2000</b> , 7, 980-2		1
29	Short communicationa simple way to obtain sufficient amounts of arterial endothelial cells from human umbilical cords. <i>Cell Biology International</i> , <b>1999</b> , 23, 89-90	4.5	7
28	Secretoneurin and neurogenic inflammation. <i>Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica</i> , <b>1999</b> , 20, 789-94		1
27	Signaling in neuropeptide-induced migration of human eosinophils. <i>Journal of Leukocyte Biology</i> , <b>1998</b> , 64, 828-34	6.5	78
26	Human and bovine endothelial cell monolayers are differentially activated for neutrophil transmigration by human plasma. <i>Annals of the New York Academy of Sciences</i> , <b>1997</b> , 832, 135-46	6.5	7
25	Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. <i>Circulation Research</i> , <b>1997</b> , 81, 963-9	15.7	70
24	SUBSTANCE P ACTS AS A CELL-CYCLE DEPENDENT MODULATOR OF HUMAN SKIN FIBROBLAST PROLIFERATION IN VITRO - INFLUENCE OF THE ARACHIDONIC ACID CASCADE. <i>Biochemical Society Transactions</i> , <b>1996</b> , 24, 509S-509S	5.1	
23	Interaction of substance P with epidermal growth factor and fibroblast growth factor in cyclooxygenase-dependent proliferation of human skin fibroblasts. <i>Journal of Cellular Physiology</i> , <b>1996</b> , 166, 601-8	7	32
22	Use of fluorochromes in the determination of chemotaxis and haptotaxis of granulocytes by micropore filter assays. <i>Annals of Hematology</i> , <b>1996</b> , 72, 23-27	3	
21	Different patterns of deactivation of chemotaxis and haptotaxis of human peripheral blood mononuclear leukocytes by soluble and surface-bound attractants. <i>Journal of Leukocyte Biology</i> , <b>1995</b> , 58, 438-44	6.5	6
20	Decreased beta-endorphin content in peripheral blood mononuclear leukocytes from patients with Crohnß disease. <i>Brain, Behavior, and Immunity,</i> <b>1994</b> , 8, 261-9	16.6	17
19	Migration of neutrophils across endothelial monolayers is stimulated by treatment of the monolayers with beta-endorphin. <i>Brain, Behavior, and Immunity,</i> <b>1994</b> , 8, 270-7	16.6	16
18	Substance P: a competence factor for human fibroblast proliferation that induces the release of growth-regulatory arachidonic acid metabolites. <i>Journal of Cellular Physiology</i> , <b>1993</b> , 156, 579-87	7	35
17	Inhibition of recombinant human growth hormone-induced and prolactin-induced activation of neutrophils by octreotide. <i>Naunyn-Schmiedeberges Archives of Pharmacology</i> , <b>1993</b> , 347, 336-41	3.4	19
16	Attraction of human monocytes by the neuropeptide secretoneurin. FEBS Letters, 1993, 334, 41-4	3.8	98

#### LIST OF PUBLICATIONS

15	Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin. <i>Blood</i> , <b>1993</b> , 82, 954-60	2.2	16	
14	Decreased immunoreactive beta-endorphin in mononuclear leucocytes from patients with rheumatic diseases. <i>Clinical and Experimental Immunology</i> , <b>1992</b> , 87, 178-82	6.2	15	
13	Proinflammatory cytokines in cardiac myxomas. <i>Journal of Internal Medicine</i> , <b>1992</b> , 232, 263-5	10.8	21	
12	Priming of polymorphonuclear neutrophils by atrial natriuretic peptide in vitro. <i>Journal of Clinical Investigation</i> , <b>1992</b> , 89, 1580-6	15.9	67	
11	Suppression of thyroid function by interferon-alpha 2 in man. <i>Naunyn-Schmiedeberge Archives of Pharmacology</i> , <b>1991</b> , 343, 665-8	3.4	8	
10	Priming of normal human neutrophils by recombinant human growth hormone. <i>British Journal of Haematology</i> , <b>1991</b> , 78, 19-22	4.5	55	
9	Plasma levels of atrial natriuretic peptide and tumor necrosis factor-alpha during transient myocardial ischemia in patients with stable angina. <i>Klinische Wochenschrift</i> , <b>1991</b> , 69, 944		4	
8	Substance P receptor-mediated secretion of respiratory glycoconjugate from feline airways in vitro. <i>Experimental Lung Research</i> , <b>1989</b> , 15, 17-29	2.3	35	
7	In vitro human polymorphonuclear leukocyte chemokinesis and human monocyte chemotaxis are different activities of aminoterminal and carboxyterminal substance P. <i>Naunyn-Schmiedeberge Archives of Pharmacology</i> , <b>1989</b> , 340, 185-90	3.4	53	
6	Interleukin-1 interaction with neuroregulatory systems: selective enhancement by recombinant human and mouse interleukin-1 of in vitro opioid peptide receptor binding in rat brain. <i>Journal of Neuroscience Research</i> , <b>1989</b> , 22, 172-80	4.4	30	
5	Bombesin-like peptides as growth factors. Wiener Klinische Wochenschrift, <b>1989</b> , 101, 435-40	2.3	1	
4	Recent research in neuroimmunomodulation: some highlights of the second international workshop, and some clinical implications of behavioral immunology. <i>International Journal of Neuroscience</i> , <b>1988</b> , 40, 263-9	2		
3	Neuromodulation by polypeptide growth factors: preliminary results on the distribution of epidermal growth factor receptors in adult brain. <i>Wiener Klinische Wochenschrift</i> , <b>1988</b> , 100, 760-3	2.3	1	
2	Phenotyping of acute and persistent COVID-19 features in the outpatient setting: exploratory analysis of an international cross-sectional online survey		1	
1	Who is at risk of poor mental health following COVID-19 outpatient management?		1	